La cadena de opciones muestra datos clave de las opciones de acciones de Alterity Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Alterity Therapeutics..

Alterity Therapeutics (NASDAQ:ATHE) Bolsa, Cadena de Opciones

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Alterity Therapeutics Ltd

ATHENS INTL ARPT S A by ATHENS INTL ARPT SA

ATHENS INTL ARPT SA U/ADR by ATHENS INTL ARPT SA

ATHENA BITCOIN GLOBAL by ATHENA BITCOIN GLOBAL

Athena Bitcoin Global

Athena Gold Corp

ATHENA GOLD CORP by Athena Gold Corporation

ATHENA TECH ACQ CP II A by Athena Technology Acquisition Corp. II

Athena Technology Acquisition Corp II

ATHENA TECH ACQ CP II UTS by Athena Technology Acquisition Corp. II

Athena Technology Acquisition Corp II Warrants (01/01/9999)

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 6.35% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Share, Series A

Athene Holding Ltd

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 5.625% Fixed Rate Perpetual Non- Cumulative Preference Share, Series B, par value $1.00 per share

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 4.875% Fixed-Rate Perpetual Non-Cumulative Preference Share, Series D

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 7.750% Fixed-Rate Reset Perpetual Non-Cumulative Preference Share, Series E

Athene Holding Ltd. 7.250% Fixed-Rate Reset Junior Subordinated Debentures due 2064

Athenex Inc

ATHENS WTR&SWGE PUB EYDAP by Athens Water & Sewage Public Co. Eydap

Athens Water Supply & Sewerage Co

Athersys Inc

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) will release earnings results for the second quarter, <a href="https://www.benzinga.com/quote/REGN/earnings">before the opening bell on Friday, Aug. 1.</a>
Analysts expect the Tarrytown, New York -based company to report quarterly earnings at $8.43 per share, down from $11.56 per share in the year-ago period. Regeneron Pharmaceuticals projects to report quarterly revenue at $3.28 billion, compared to $3.55 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy.
Regeneron Pharmaceuticals shares fell 1.6% to close at $545.46 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/regn/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>UBS analyst Trung Huynh maintained a Neutral rating and raised the price target from $560 to $584 on July 11, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and cut the price target from $755 to $754 on July 10, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Citigroup analyst Geoff Meacham maintained a Buy rating and cut the price target from $700 to $650 on June 2, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight and cut the price target from $700 to $580 on May 30, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Guggenheim analyst Yatin Suneja maintained a Buy rating and slashed the price target from $940 to $810 on May 1, 2025. This analyst has an accuracy rate of 60%.</li>
</ul>
Considering buying REGN stock? Here&#8217;s what analysts think:
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46757288/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

REGN

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

As President Donald Trump unveiled a blitz of new tariffs across <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46781583/trump-slaps-35-tariff-on-canadian-goods-hits-68-other-nations-with-new-trade-war-amid-fentanyl-security-china-tensions">different countries on Thursday</a>, the markets remained largely unfazed by the move.
What Happened: On Thursday, in a post on X, The Kobeissi Letter highlighted the market&#8217;s muted response to Trump&#8217;s sweeping new moves on the trade and tariff front. 
The post notes that Trump &#8220;randomly&#8221; increased tariffs on Canada, the largest trading partner of the United States, from 25% to 35%. Followed by a string of new tariffs on others, such as &#8220;Vietnam, Switzerland, South Africa, Taiwan, Cambodia, Thailand, Malaysia, Indonesia, Turkey, and Venezuela.&#8221;
See Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46758722/the-5-billion-copper-trap-how-one-etf-got-burned-by-trumps-surprise-tariff-move">The $5 Billion Copper Trap: How One ETF Got Burned By Trump&#8217;s Surprise Tariff Move</a>
Yet, the market response was underwhelming, with S&amp;P 500 futures &#8220;down a mere 10 points,&#8221; which the post attributes almost entirely to &#8220;Amazon&#8217;s weak earnings results.&#8221;
It says that in April, when the &#8220;Liberation Day&#8221; tariffs were first announced, such a move would have sent the S&amp;P 500 lower by 3% or more. 
The post says &#8220;the trade war has lost all credibility&#8221; in the market, and that it has lost the &#8220;shock effect&#8221; that it had a couple of months ago. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The market says the trade war has lost all credibility: President Trump just seemingly just randomly decided to raise tariffs on Canada from 25% to 35%. On top of this, he imposed &quot;reciprocal tariffs&quot; on Vietnam, Switzerland, South Africa, Taiwan, Cambodia, Thailand, Malaysia,…
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1951078173153607990?ref_src=twsrc%5Etfw">August 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: This could be seen as a fallout of the &#8220;TACO Trade&#8221; meme, or &#8220;Trump Always Chickens Out,&#8221; where investors buy equities right after Trump makes a tariff threat, knowing fully well that he will eventually back out. 
Economist Peter Schiff recently called this &#8220;a classic paradox,&#8221; since markets not <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46434910/trump-wont-chicken-out-again-peter-schiff-warns-of-classic-paradox-that-might-make-a-selloff-inevitable">reacting to Trump&#8217;s tariffs</a>, because they expect him to &#8220;chicken out,&#8221; will eventually lead him to follow through on his threats. 
&#8220;Investors assume Trump will cancel the August 1 tariffs before they kick in, so stocks aren&#8217;t selling off,&#8221; he says, but since there isn&#8217;t a dramatic market response to this, &#8220;Trump won&#8217;t chicken out again.&#8221;
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/08/46781753/kevin-oleary-backs-trumps-tariff-strategy-calls-it-a-value-added-tax-says-he-can-be-very-pragmatic">Kevin O&#8217;Leary Backs Trump&#8217;s Tariff Strategy: Calls It a &#8216;Value-Added Tax,&#8217; Says He Can Be &#8216;Very Pragmatic&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

'The Trade War Has Lost All Credibility:' Markets Shrug Off Trump's Tariff Blitz On Multiple Countries

GoPro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NASDAQ">GPRO</a>) shares dropped 6.98% in after-hours trading on Thursday, continuing a decline from recent meme stock highs as retail investor enthusiasm wanes.
What Happened: The action camera maker closed regular trading at $1.29, down 3.73% for the session. After-hours trading saw the stock fall further to $1.20, extending losses from a peak reached last month, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
GoPro&#8217;s stock rally began July 17 at $0.78 and peaked at $1.53 on July 23, driven by renewed meme stock fervor among retail investors. The surge mirrored earlier rallies in GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) and AMC Entertainment Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>).
The July rally was fueled by short squeeze dynamics, with short i<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46581870/gopro-stock-surges-as-meme-frenzy-short-squeeze-potential-collide">nterest at 9.43% creating buying pressure</a> as bearish investors covered positions. The stock&#8217;s Relative Strength Index reached 88 during the peak, indicating heavily overbought conditions that typically signal potential pullbacks.
Fundamental factors <a href="https://www.benzinga.com/markets/equities/25/07/46565073/gopros-stock-soars-60-after-hours-heres-whats-going-on">initially supported the momentum</a>. GoPro won a patent infringement ruling against Insta360, with CEO Nicholas Woodman stating the company &#8220;will not sit idle while we believe others unjustly take advantage of our hard work, investment and innovation.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/25/08/46784693/dow-falls-over-300-points-despite-strong-earnings-investor-sentiment-declines-fear-index-remains-in-greed-zone">Dow Falls Over 300 Points Despite Strong Earnings: Investor Sentiment Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a>
Why It Matters: The company also provided optimistic second-quarter guidance in May. Sales projections of $135 million to $155 million exceeded <a href="https://www.benzinga.com/markets/equities/25/07/46565073/gopros-stock-soars-60-after-hours-heres-whats-going-on">the estimated $124.65 million</a>.
The convergence of retail trading activity and improving company fundamentals created significant price swings, with GoPro&#8217;s market capitalization <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46581870/gopro-stock-surges-as-meme-frenzy-short-squeeze-potential-collide">surpassing $250 million</a> during the rally&#8217;s peak.
Despite positive developments, including Thursday&#8217;s announcement of an opt-in AI training program allowing subscribers to monetize cloud-based video content, the stock has declined from peak levels. 
Price Action: Friday premarket trading showed shares at $1.23, down 4.65%, reflecting the volatility characteristic of meme stock movements.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/08/46785080/jim-cramer-calls-figma-too-expensive-at-50x-sales-stock-surges-250-on-market-debut">Jim Cramer Calls Figma &#8216;Too Expensive&#8217; At 50x Sales — Stock Surges 250% On Market Debut</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

GPRO

GoPro Slides Nearly 5% In Premarket As Meme Stock Sugar Rush Fades

Piper Sandler analyst Brent Bracelin maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Overweight and raises the price target from $75 to $82.

PCOR

Piper Sandler Maintains Overweight on Procore Technologies, Raises Price Target to $82

Piper Sandler analyst Brent Bracelin upgrades AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) from Neutral to Overweight and raises the price target from $240 to $350.

Upgrades

APPF

Piper Sandler Upgrades AppFolio to Overweight, Raises Price Target to $350

OpenAI has decided to retract a new feature from its ChatGPT app that enabled users to make their private conversations discoverable by search engines. This decision comes in the wake of worries about accidental oversharing.
<h2 class="wp-block-heading">ChatGPT Sharing Feature Pulled Over Google Indexing Risks</h2>
The &#8220;Make this chat discoverable&#8221; feature, which was an opt-in, was intended to help users find useful conversations. However, it was removed due to concerns about security and privacy, as announced by Dane Stuckey, OpenAI&#8217;s chief information security officer, through a X post on Thursday. 
Stuckey stated, &#8220;Ultimately we think this feature introduced too many opportunities for folks to accidentally share things they didn&#8217;t intend to, so we&#8217;re removing the option.&#8221; He also noted that OpenAI is taking steps to remove indexed content from applicable search engines.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We just removed a feature from <a href="https://twitter.com/ChatGPTapp?ref_src=twsrc%5Etfw">@ChatGPTapp</a> that allowed users to make their conversations discoverable by search engines, such as Google. This was a short-lived experiment to help people discover useful conversations. This feature required users to opt-in, first by picking a chat… <a href="https://t.co/mGI3lF05Ua">pic.twitter.com/mGI3lF05Ua</a>
&mdash; DANΞ (@cryps1s) <a href="https://twitter.com/cryps1s/status/1951041845938499669?ref_src=twsrc%5Etfw">July 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The decision to remove the feature came after concerns were raised by newsletter writer Luiza Jarovsky that private conversations with ChatGPT were being made public, <a href="https://www.businessinsider.com/openai-removes-chatgpt-feature-over-search-engine-privacy-concerns-2025-7?ref=biztoc.com">reported </a>Business Insider. Jarovsky noted that when using the chatbot&#8217;s sharing feature, users were inadvertently allowing their exchanges to be indexed by Google (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).  Users had to take actions to share their chats, including ticking a box to &#8220;make this chat discoverable,&#8221; which would then appear in web searches. The shared chats were anonymized to reduce the risk of personal identification.
<h2 class="wp-block-heading">Altman Sounds Alarm on AI Risks and ChatGPT Confidentiality</h2>
This incident comes in the wake of OpenAI CEO&nbsp;<a href="https://www.benzinga.com/markets/tech/25/07/46744816/sam-altman-warns-chatgpt-conversations-arent-protected-like-talking-with-your-psychologist-or-lawyer-we-could-be-required-to-produce-that-in-court">Sam Altman&#8217;s warning</a>&nbsp;about the lack of legal confidentiality for ChatGPT conversations. Altman cautioned that sensitive chats could be subject to court subpoenas, as the platform does not offer the same legal protections as a doctor, lawyer, or licensed mental health professional.
Earlier, Altman had also expressed concerns about the potential threats artificial intelligence (AI) poses to financial security, urging them to stay ahead of the technology. He specifically highlighted the use of voice prints for high-value transactions, indicating the dangers of AI outsmarting current authentication methods. This rollback by OpenAI is a step towards addressing these concerns and ensuring user privacy and data security.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46647201/openai-chairman-says-only-tech-giants-can-afford-new-ai-models-startups-should-focus-on-applications">OpenAI Chairman Says Only Tech Giants Can Afford New AI Models—Startups Should Focus On Applications</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

GOOG

GOOGL

OpenAI Pulls ChatGPT's 'Discoverable' Feature Over Privacy Concerns: 'Too Many Opportunities...To Accidentally Share Things'

Guidance

Magna International Raises FY2025 Sales Guidance from $40.00B-$41.60B to $40.40B-$42.00B vs $40.04B Est

Li Auto Delivers 30,731 Vehicles In July 2025, Launches Li i8 SUV, Reaches 1.37 Million Cumulative Deliveries

Magna International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MG#TSX">MG</a>) reported quarterly earnings of $1.44 per share which beat the analyst consensus estimate of $0.76 by 89.47 percent. This is a 6.67 percent increase over earnings of $1.35 per share from the same period last year. The company reported quarterly sales of $10.631 billion which beat the analyst consensus estimate of $6.302 billion by 68.70 percent. This is a 2.98 percent decrease over sales of $10.958 billion the same period last year.

Earnings Beats

TSX:MG

Magna International Q2 Adj. EPS $1.44 Beats $0.76 Estimate, Sales $10.631B Beat $6.302B Estimate

Magna International Q2 Adj. EPS $1.44 Beats $1.13 Estimate, Sales $10.63B Beat $10.08B Estimate

Design platform Figma Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIG#NYSE">FIG</a>) defied Jim Cramer&#8217;s warnings about its valuation, surging 250% to $115.50 on its market debut on Thursday after pricing its IPO at $33 per share on Wednesday evening.
<h2 class="wp-block-heading">Cramer Warns of Overvaluation</h2>
Hours before trading began, CNBC host Cramer posted multiple warnings on social media, calling Figma &#8220;way too expensive&#8221; at 54 times sales, assuming a 40% growth rate. He urged investors to &#8220;pull&#8221; market orders, predicting they could &#8220;get it lower.&#8221;
&#8220;If you are putting in a market order from Figma you should pull it now. You will get it lower. It is near 50x sales!!!!&#8221; Cramer posted 17 hours before market open.
The Mad Money host later acknowledged the stock remained &#8220;too high&#8221; but noted investors were &#8220;getting too excited and paying these prices.&#8221;
The surge aligns with the &#8220;Inverse Cramer&#8221; phenomenon, where stocks often move opposite to Cramer&#8217;s predictions. The Inverse Cramer Tracker ETF (SJIM) was liquidated in February 2024 after tracking this pattern, with creator Matthew Tuttle stating the fund accomplished its mission of highlighting &#8220;the danger of following TV stockpickers.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If you are putting in a market order from Figma you should pull it now. You will get it lower .It is near 50x sales!!!!
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1950945696724480105?ref_src=twsrc%5Etfw">July 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The history of paying up like this is not very good&#8230;.FIG
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1950969498275815852?ref_src=twsrc%5Etfw">July 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Figma still too high, but i can see people getting too excited and paying these prices&#8230; but it is way too expensive,assuming 40% growth rate &#8212; 54 x sales. One of most expensive stocks in the market, Second only to Palantir?
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1950980492863451338?ref_src=twsrc%5Etfw">July 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">Strong IPO Performance Despite Concerns</h2>
Figma raised approximately $411 million by offering 36.9 million Class A shares at $33 each. The San Francisco-based company&#8217;s shares opened dramatically higher, reaching $143.45 in after-hours trading — a 24.2% additional gain.
Morgan Stanley, Goldman Sachs Group Inc., Allen &amp; Company LLC and JPMorgan Chase &amp; Co. served as joint lead book-running managers.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46781140/tim-cook-says-apple-is-very-open-to-ai-acquisitions-amid-mounting-pressure-to-catch-up-with-google-meta-and-microsoft">Tim Cook Says Apple Is &#8216;Very Open&#8217; To AI Acquisitions Amid Mounting Pressure To Catch Up With Google, Meta And Microsoft</a>
<h2 class="wp-block-heading">Solid Fundamentals Drive Investor Interest</h2>
The collaborative design platform reported $749 million in revenue for 2024, marking 48% year-over-year growth. First quarter 2025 revenue reached $228.2 million, up 46% from the prior year period.
Figma serves 95% of Fortune 500 companies and 78% of <a href="https://www.benzinga.com/markets/ipos/25/07/46212893/figma-targets-wall-street-debut-after-20-billion-adobe-deal-collapse">Forbes Global 2000 firms</a>. Major clients include Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) and Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>). The company&#8217;s Net Dollar Retention Rate was 134% at year-end 2024.
<h2 class="wp-block-heading">Meme Stock Potential Predicted</h2>
Nikita Bier, Head of Product at Elon Musk&#8216;s X platform, predicted Figma &#8220;is going to be a meme stock beyond all comprehension&#8221; <a href="https://www.benzinga.com/markets/equities/25/07/46748648/figma-could-become-a-meme-stock-beyond-all-comprehension-warns-elon-musks-x-product-head-nikita-bier">ahead of the IPO</a>. Research <a href="https://www.benzinga.com/markets/penny-stocks/25/07/46681079/wall-street-is-getting-in-on-meme-stock-action-40-of-hedge-funds-now-use-social-sentiment-tools-hire-social-media-savvy-analysts">shows 40% of hedge funds</a> now use social sentiment analytics for trading strategies in 2025, compared to 10% three years ago.
The IPO follows the collapsed $20 billion acquisition by Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) due to regulatory concerns. 
Price Action: Figma is trading higher in Friday's premarket session, up 12.03% to $131.74, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/08/46783783/redditors-100-chatgpt-day-trading-experiment-trounces-two-benchmark-indexes-with-24-returns-heres-how-it-pulled-it-off">Redditor&#8217;s $100 ChatGPT Day-Trading Experiment Trounces Two Benchmark Indexes With 24% Returns — Here&#8217;s How It Pulled It Off</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: M.oo / Shutterstock.com

ADBE

MSFT

Jim Cramer Calls Figma 'Too Expensive' At 50x Sales — Stock Surges 250% On Market Debut

Intel Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) new CEO, Lip-Bu Tan, is overhauling the chipmaker's manufacturing operations, <a href="https://www.benzinga.com/markets/tech/25/07/46621426/intel-ceo-says-hes-making-hard-but-necessary-decisions-as-chipmaker-announces-massive-layoffs-project-cancellations">cutting thousands of jobs</a>, delaying projects and witnessing the retirement of key executives as part of a sweeping reset.
<h2 class="wp-block-heading">Three Senior Intel Executives Step Down Amid Restructuring</h2>
Three senior Intel executives are set to retire amid a broad restructuring of the company's manufacturing division, reported Reuters on Thursday.
Corporate Vice Presidents Kaizad Mistry and Ryan Russell of the Technology Development Group, along with Gary Patton, VP of Design Technology Platform and a former IBM executive, will depart the company, the report said.
The changes come as Tan implements a plan to streamline operations and boost efficiency.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/earnings/25/07/46601720/american-airlines-cfo-declares-worst-is-over-but-cautious-outlook-sinks-stock" target="_blank" rel="noreferrer noopener">American Airlines CFO Declares Worst Is Over, But Cautious Outlook Sinks Stock</a>
<h2 class="wp-block-heading">Tan Targets 31% Workforce Reduction By Year-End</h2>
Tan, who <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44767888/how-intels-ceo-pick-could-jolt-chip-stocks-and-etfs">became CEO in March</a>, is aggressively downsizing. He aims to reduce Intel's global workforce to 75,000 employees by year-end—a roughly 31% drop from the 108,900 reported at the end of 2024.&nbsp;
"I know the past few months have not been easy," Tan said in a memo to employees last month. "We are making hard but necessary decisions to streamline the organization, drive greater efficiency and increase accountability at every level of the company."
<h2 class="wp-block-heading">Foundry Cuts, Global Moves And Delayed Ohio Plant</h2>
As part of the shake-up, Intel is <a href="https://www.benzinga.com/markets/tech/25/07/46199580/microsoft-rivian-intel-slash-jobs-in-june-tech-layoff-spree">cutting 15% to 20% of jobs</a> in its Foundry division, reducing manufacturing capacity planning teams and relocating some assembly and testing operations from Costa Rica to Vietnam and Malaysia.
Construction of Intel's long-awaited semiconductor facility in Ohio will also be "further" delayed, Tan confirmed. Additionally, Intel is pausing expansion plans in Germany and Poland.
<h2 class="wp-block-heading">14A And 18A Chip Ambitions Now Tied To Customer Demand</h2>
Tan's aggressive restructuring signals a shift in Intel's strategic priorities as it <a href="https://www.benzinga.com/markets/tech/25/06/46058862/nvidia-intel-chip-stocks-ai-valuation-revenue">struggles to regain leadership</a> in chip manufacturing. His plans include a more disciplined approach to manufacturing investment—particularly around the next-gen 14A and 18A processes.
Intel said development of the 14A process will depend on securing a significant customer. Without one, it may suspend or cancel the project. The 18A process, meanwhile, may be reserved for in-house use only, despite earlier plans to offer it to external clients.
Intel reported better-than-expected <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46617195/intel-q2-earnings-revenue-beat-eps-miss-chipmaker-sees-clear-opportunities-to-enhance-competitive-position">second-quarter revenue</a> of $12.86 billion, but missed earnings estimates with a loss of 10 cents per share.
Price Action: Intel shares dropped 2.65% during Thursday&#8217;s regular session and slipped a further 0.71% in after-hours trading, according to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0717">Benzinga Pro</a>.
Benzinga's Edge Stock Rankings show that INTC continues to exhibit downward momentum across short, medium and long-term timeframes. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">More detailed performance insights are available here</a>.
<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01041736/Screenshot-2025-08-01-at-1.38.31%E2%80%AFPM.png" alt="" class="wp-image-1010384" /></a></figure>
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45396297/cathie-wood-dumps-palantir-as-stock-touches-peak-prices-bails-on-soaring-flying-taxi-maker-archer-aviation" target="_blank" rel="noreferrer noopener">Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

INTC

Intel Exec Exodus As CEO Lip-Bu Tan Slashes Workforce, Delays Ohio Chip Plant In Major Shake-Up: Report

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) will release earnings results for the second quarter, before the opening<a href="https://www.benzinga.com/quote/MRNA/earnings"> bell on Friday, Aug. 1</a>.
Analysts expect the Cambridge, Massachusetts-based company to report quarterly loss at $2.97 per share, versus a year-ago loss of $3.33 per share. Moderna projects to report quarterly revenue at $112.96 million, compared to $241 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 31, Moderna announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.
Moderna shares fell 8.1% to close at $29.56 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/mrna/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>JP Morgan analyst Jessica Fye maintained an Underweight rating and cut the price target from $33 to $26 on May 22, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Evercore ISI Group analyst Cory Kasimov maintained an In-Line rating and cut the price target from $50 to $32 on May 2, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and cut the price target from $39 to $32 on April 9, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Citigroup analyst Geoff Meacham initiated coverage on the stock with a Neutral rating and a price target of $40 on March 13, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Argus Research analyst John Eade downgraded the stock from Buy to Hold on Dec. 18, 2024. This analyst has an accuracy rate of 73%.</li>
</ul>
Considering buying MRNA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01043632/image-5-1024x576.png" alt="" class="wp-image-1010426" style="width:711px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01043632/image-5-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01043632/image-5-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01043632/image-5-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01043632/image-5.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46757288/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

MRNA

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

<h3>Companies Reporting Before The Bell</h3>
• Brookfield Business (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBUC#NYSE">BBUC</a>) is expected to report earnings for its second quarter. 
• TELUS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $3.68 billion. 
• Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) is expected to report quarterly earnings at $1.30 per share on revenue of $2.32 billion. 
• IES Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is likely to report earnings for its third quarter. 
• EchoStar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) is estimated to report quarterly loss at $1.04 per share on revenue of $3.83 billion. 
• CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $4.51 billion. 
• Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) is expected to report quarterly earnings at $0.85 per share on revenue of $1.48 billion. 
• Patria Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAX#NASDAQ">PAX</a>) is projected to report quarterly earnings at $0.29 per share on revenue of $85.67 million. 
• Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) is estimated to report quarterly earnings at $0.24 per share on revenue of $1.95 billion. 
• Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) is projected to report quarterly loss at $0.55 per share on revenue of $1.20 billion. 
• Kimberly-Clark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $4.80 billion. 
• Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is estimated to report quarterly earnings at $0.89 per share on revenue of $5.05 billion. 
• Avient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $852.02 million. 
• Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) is expected to report quarterly earnings at $1.53 per share on revenue of $81.31 billion. 
• RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) is expected to report quarterly earnings at $2.67 per share on revenue of $432.15 million. 
• Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) is likely to report quarterly earnings at $7.55 per share on revenue of $3.31 billion. 
• Perella Weinberg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $140.70 million. 
• Piper Sandler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>) is expected to report quarterly earnings at $2.13 per share on revenue of $350.93 million. 
• nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) is projected to report quarterly earnings at $0.79 per share on revenue of $907.82 million. 
• Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) is projected to report quarterly loss at $2.98 per share on revenue of $119.02 million. 
• AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $20.61 million. 
• Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) is likely to report quarterly earnings at $1.70 per share on revenue of $45.88 billion. 
• Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) is estimated to report quarterly earnings at $0.68 per share on revenue of $3.67 billion. 
• BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $2.99 billion. 
• Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) is expected to report quarterly earnings at $1.10 per share on revenue of $1.01 billion. 
• iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is estimated to report quarterly earnings at $0.43 per share on revenue of $20.13 million. 
• Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $141.11 million. 
• AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $45.61 million. 
• Dorian LPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPG#NYSE">LPG</a>) is estimated to report quarterly earnings at $0.61 per share on revenue of $86.50 million. 
• Escalade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESCA#NASDAQ">ESCA</a>) is likely to report earnings for its second quarter. 
• Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) is projected to report quarterly earnings at $1.17 per share on revenue of $10.39 billion. 
• LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) is estimated to report quarterly earnings at $0.85 per share on revenue of $7.47 billion. 
• W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) is expected to report quarterly earnings at $10.04 per share on revenue of $4.52 billion. 
• Fortis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTS#NYSE">FTS</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $2.01 billion. 
• Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) is estimated to report quarterly earnings at $2.43 per share on revenue of $573.80 million. 
• Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEPC#NYSE">BEPC</a>) is expected to report quarterly loss at $0.18 per share on revenue of $1.68 billion. 
• TransAlta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAC#NYSE">TAC</a>) is expected to report earnings for its second quarter. 
• MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is expected to report quarterly earnings at $0.76 per share on revenue of $6.30 billion. 
• Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $203.89 million. 
• Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) is projected to report quarterly earnings at $4.03 per share on revenue of $8.37 billion. 
• Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) is estimated to report quarterly earnings at $2.78 per share on revenue of $1.89 billion. 
• Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) is estimated to report quarterly earnings at $0.50 per share on revenue of $10.01 billion. 
• Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $936.89 million. 
• Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>) is expected to report quarterly loss at $0.30 per share on revenue of $1.38 billion. 
• Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $2.35 billion. 
• Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $1.68 billion. 
• Johnson Outdoors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOUT#NASDAQ">JOUT</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $172.95 million. 
• Xenia Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $273.33 million. 
• T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) is expected to report quarterly earnings at $2.10 per share on revenue of $1.73 billion. 
• TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $660.86 million. 
• Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) is expected to report quarterly earnings at $2.96 per share on revenue of $2.66 billion. 
• Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) is projected to report quarterly earnings at $1.22 per share on revenue of $10.54 billion. 
• Insperity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) is likely to report quarterly earnings at $0.25 per share on revenue of $1.67 billion. 
• Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) is projected to report quarterly loss at $0.06 per share on revenue of $23.89 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is projected to report quarterly loss at $0.05 per share on revenue of $770 thousand. 
• Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) is projected to report quarterly loss at $0.33 per share on revenue of $76.08 million. 
• AdvanSix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) is estimated to report earnings for its second quarter. 
• Interface (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) is estimated to report quarterly earnings at $0.47 per share on revenue of $360.34 million. 
• Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) is projected to report quarterly earnings at $0.57 per share on revenue of $4.66 billion. 
• Brookfield Bus Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBU#NYSE">BBU</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $2.80 billion. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ARES

ASIX

AVNT

AVTR

BBUC

BEPC

BFLY

BTSG

CBOE

ESCA

FLGT

IESC

INGR

IRMD

JOUT

LBTYA

MITT

OCGN

PIPR

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

SATS

TILE

TIXT

TROW

Earnings Scheduled For August 1, 2025

President Donald Trump criticized Canada's move to back statehood for Palestine as a major roadblock to a new trade deal, even as his administration announced a new partnership with Pakistan, a country that does not recognize Israel.
What Happened: The conflicting approaches to foreign policy were highlighted by a series of statements and social media posts from the White House and other news outlets on Thursday.
In a post on Truth Social, President Trump declared, &#8220;Wow! Canada has just announced that it is backing statehood for Palestine. That will make it very hard for us to make a Trade Deal with them.&#8221;
<figure class="wp-block-image size-full"><a href="https://truthsocial.com/@realDonaldTrump/posts/114945962278773358"><img loading="lazy" decoding="async" width="679" height="222" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01013846/Trump-Canada.png" alt="" class="wp-image-1010204" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01013846/Trump-Canada.png 679w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01013846/Trump-Canada-300x98.png 300w" sizes="(max-width: 679px) 100vw, 679px" /></a></figure>
The statement came just ahead of an Aug. 1st deadline for new U.S. trading terms, with<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46747584/trump-blasts-canada-over-palestine-stance-says-it-makes-striking-a-trade-deal-with-"> Canada facing a potential 35% tariff</a> on goods not covered by the USMCA agreement. 
Canadian Prime Minister Mark Carney announced that his country's recognition of a Palestinian state at the UN General Assembly would be predicated on reforms excluding Hamas.
Meanwhile, in a separate Truth Social post, Trump detailed a <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46745168/trump-leaves-good-friend-india-in-the-cold-strikes-trade-deal-with-arch-rival-pakistan-over-massive-oil-reserves">new deal with Pakistan</a>. &#8220;We have just concluded a Deal with the Country of Pakistan, whereby Pakistan and the United States will work together on developing their massive Oil Reserves,&#8221; he wrote.
This partnership with Pakistan is notable given the country's strong anti-Israel stance, as detailed in a report <a href="https://crescent.icit-digital.org/articles/why-pakistan-should-not-recognize-israel">from</a> the Islamic newsmagazine Crescent International.
The magazine reported on an ongoing debate within Pakistan about whether to recognize Israel, with the majority of arguments against recognition, calling it a &#8220;colonial settler entity.&#8221;
<figure class="wp-block-image size-full"><a href="https://truthsocial.com/@realDonaldTrump/posts/114943927434273211"><img loading="lazy" decoding="async" width="691" height="664" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01013858/Trump-Pak.png" alt="" class="wp-image-1010205" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01013858/Trump-Pak.png 691w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01013858/Trump-Pak-300x288.png 300w" sizes="(max-width: 691px) 100vw, 691px" /></a></figure>
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46753311/delusional-world-analyst-slams-jerome-powells-inaction-as-experts-debate-possibility-of-six-cuts-starting-september">&#8216;Delusional World:&#8217; Analyst Slams Jerome Powell&#8217;s Inaction As Experts Debate Possibility Of Six Cuts Starting September</a>
Why It Matters: According to Reuters, Canada is the second-largest U.S. trading partner, following Mexico. It bought $349.4 billion of U.S. goods last year and exported $412.7 billion to the U.S.
Meanwhile, as per the <a href="https://ustr.gov/countries-regions/south-central-asia/pakistan#:~:text=Pakistan%20Trade%20Summary,(%2490.9%20million)%20from%202023.">U.S. Trade Representative</a> (USTR), total goods trade with Pakistan was an estimated $7.3 billion in 2024. U.S. goods exports to Pakistan in 2024 were $2.1 billion, up 4.4% or $90.9 million from 2023. 
The contrast between Trump's condemnation of Canada and his new deal with Pakistan, a non-recognizing nation, underscores a seemingly inconsistent foreign policy driven by trade priorities.
Trump told reporters on Tuesday this week that <a href="https://www.benzinga.com/news/politics/25/07/46714946/trump-warns-india-of-25-tariffs-as-trade-talks-stall-ahead-of-august-1-deadline">India could face tariffs of 20% to 25%</a> on exports to the United States as the Aug. 1 deadline approaches without a finalized agreement. As per <a href="https://ustr.gov/countries-regions/south-central-asia/india">USTR</a>, India exports nearly $130 billion of goods to the U.S. 
On Wednesday, in a Truth Social post, Trump added that India will also face a &#8220;penalty" for buying Russian energy and military equipment, "at a time when everyone wants Russia to STOP THE KILLING IN UKRAINE," he says.
Meanwhile, the U.S. Commerce Secretary Howard Lutnick warned that Aug. 1 would be the &#8220;<a href="https://www.benzinga.com/news/politics/25/07/46716020/trump-is-yet-to-sign-a-trade-deal-with-over-85-of-humanity-here-are-the-major-countries-that-are-ye">hard deadline</a>&#8221; for countries that haven&#8217;t yet signed a trade deal with the U.S. to start paying the tariffs. 
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined on Thursday. The SPY was down 0.38% at $632.08, while the QQQ declined 0.53% to $565.01, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46687204/warren-buffett-has-56-of-his-258-billion-portfolios-value-exposed-to-ai-here-are-the-5-stocks-that-are-leveraging-ai-within-berkshires-holdings" target="_blank" rel="noreferrer noopener">Warren Buffett Has 56% Of His $258 Billion Portfolio's Value Exposed To AI: Here Are The 5 Stocks That Are Leveraging AI Within Berkshire's Holdings</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Trump Slams Canada's Palestine Recognition As Roadblock In Trade Deal—Signs Agreement With Pakistan That Doesn't Even Recognize Israel

Elon Musk, the CEO of Tesla Inc. and SpaceX, donated $15 million to President Donald Trump and the Republican Party, days before he called for the formation of a third party.
<h2 class="wp-block-heading">Musk&#8217;s Donations Disclosed In Campaign Finance Report</h2>
Musk made the donations in late June. The donations were disclosed in the campaign finance reports of the pro-Trump MAGA Inc., Senate Leadership Fund,&nbsp;and Congressional Leadership Fund super&nbsp;PACs, <a href="https://us.cnn.com/2025/08/01/politics/trump-maga-inc-fundraising">reported </a>CNN.
On June 27, Musk contributed $5 million each to pro-Trump MAGA Inc., the Senate Leadership Fund and the Congressional Leadership Fund. The donations were disclosed in the campaign finance report of each entity. However, on June 30, he threatened to establish a third party, the America Party, if Congress passed the &#8220;big, beautiful bill.&#8221; Musk also donated over $45 million to the America PAC in the first half of 2025.
See Also:&nbsp;<a href="https://benzinga.com/pressreleases/24/10/ab41310379/claritycheck-launches-innovative-reverse-lookup-tool-to-empower-users-against-digital-scams" target="_blank" rel="noreferrer noopener">ClarityCheck Launches Innovative Reverse Lookup Tool to Empower Users Against Digital Scams &#8211; Benzinga</a>
<h2 class="wp-block-heading">Trump's MAGA Inc. Raises Nearly $200 Million For 2026 Midterms</h2>
The Republican Party, under Trump&#8217;s leadership, has been aggressively&nbsp;fundraising&nbsp;for the 2026 midterm elections. Trump&#8217;s super PAC, MAGA Inc., raised $177 million in the first half of the year, leaving it with nearly $200 million in available funds. 
Besides Musk, the donor list featured billionaire Wall Street trader Jeffrey Yass with a $16 million contribution, cosmetics heir Ronald Lauder with $5 million, and Silicon Valley investor Marc Andreessen, who donated $3 million.
<h2 class="wp-block-heading">Trump-Musk Rift Complicates SpaceX's Role In US Defense</h2>
Musk&#8217;s relationship with the Trump administration has been tumultuous since he left in late May. Musk&#8217;s donations to the Republican Party and his subsequent change of heart are noteworthy in the context of the current political landscape.&nbsp;
Musk has been publicly critical of Trump&#8217;s policies, such as the axing of subsidies on renewable energy. This criticism has been accompanied by Musk&#8217;s&nbsp;<a href="https://www.benzinga.com/markets/tech/25/07/46623210/elon-musk-slams-trump-for-axing-subsidies-on-renewable-energy-says-spacex-won-nasa-contracts-by-doing-a-better-job-for-less-money">assertion</a>&nbsp;that SpaceX won NASA contracts by delivering superior performance at lower costs.&nbsp;
Meanwhile, the Trump administration&#8217;s reported consideration of other partners, including Amazon&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Project Kuiper, for the Golden Dome missile defense system has raised questions about SpaceX&#8217;s future role in national defense projects.
READ MORE: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46716069/elon-musk-wants-25-voting-control-in-tesla-data-shows-ev-giant-has-highest-retail-ownership-among-trillion-dollar-companies">Elon Musk Wants 25% Voting Control In Tesla: Data Shows EV Giant Has Highest Retail Ownership Among Trillion Dollar Companies</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AMZN

Elon Musk Donated $15 Million To Trump's MAGA And GOP Just 3 Days Before His Third Party Bid

The CNN Money Fear and Greed index showed further decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled mostly lower on Thursday, with the Dow Jones index falling more than 300 points during the session.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) jumped 11% after delivering blockbuster second-quarter results and upbeat revenue guidance. Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) climbed about 4% after reporting strong Azure revenues.
The combined market value of the Magnificent Seven swelled past $19.4 trillion, with both Microsoft and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) worth more than $4 trillion.
On the economic data front, the Personal Consumption Expenditures (PCE) price index rose to 2.6% in June from 2.3% in May, surpassing the 2.5% forecast. Core PCE, the Fed&#8217;s preferred inflation gauge, held at 2.8%, above the 2.7% consensus. U.S. initial jobless claims rose by 1,000 from the previous week to 218,000 in the fourth week of July, compared to market estimates of 224,000.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, real estate and health care stocks recording the biggest losses on Thursday. However, communication services and utilities stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by 330 points to 44,130.98 on Thursday. The S&amp;P 500 fell 0.37% to 6,339.39, while the Nasdaq Composite slipped 0.03% to 21,122.45 during Thursday's session.
Investors are awaiting earnings results from Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and WW Grainger Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 62.5, the index remained in the &#8220;Greed&#8221; zone on Wednesday, versus a prior reading of 65.3.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46757288/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

NVDA

Dow Falls Over 300 Points Despite Strong Earnings: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) will release earnings results for the second quarter before the <a href="https://www.benzinga.com/quote/CVX/earnings">opening bell on Friday, Aug. 1.</a>
Analysts expect the Houston, Texas-based company to report quarterly earnings at $1.75 per share, down from $2.55 per share in the year-ago period. Chevron is projected to report quarterly revenue of $45.59 billion, compared to $51.18 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Chevron has won a dispute with Exxon Mobil over Hess Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESS#NYSE">HESS</a>) offshore oil assets in Guyana. Exxon CEO Darren Woods confirmed the latest news in an interview with CNBC on July 18.
Chevron shares fell 1.3% to close at $151.64 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GBX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Roger Read maintained an Overweight rating and raised the price target from $165 to $178 on July 23, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Piper Sandler analyst Ryan Todd maintained an Overweight rating and raised the price target from $162 to $164 on July 2, 2025. This analyst has an accuracy rate of 68%.</li>
<li>HSBC analyst Kim Fustier downgraded the stock from Buy to Hold and cut the price target from $176 to $158 on May 13, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Redburn Atlantic analyst Peter Low downgraded the stock from Neutral to Sell and cut the price target from $156 to $124 on April 23, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Raymond James analyst Justin Jenkins maintained an Outperform rating and cut the price target from $180 to $175 on Feb. 3, 2025. This analyst has an accuracy rate of 77%</li>
</ul>
Considering buying CVX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/CVX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01041739/image-4-1024x563.png" alt="" class="wp-image-1010385" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01041739/image-4-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01041739/image-4-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01041739/image-4-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01041739/image-4.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46757288/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

HESS

Top Wall Street Forecasters Revamp Chevron Expectations Ahead Of Q2 Earnings

Venture capitalist&nbsp;Tim Draper&nbsp;envisioned a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and blockchain-centric ecosystem, following the launch of the SEC&#8217;s &#8220;Project Crypto&#8221; initiative on Thursday. 
What Happened: In an X post, Draper expressed excitement at the &#8220;awesome&#8221; initiative unveiled by SEC Chair Paul Atkins, hoping it would turn his vision of a Bitcoin-centric future into reality.
&#8220;My hopes to raise a fund all in Bitcoin, invest it all in Bitcoin, and have startups pay all their employees and suppliers in bitcoin, with all the accounting done on the blockchain with smart contracts is in sight,&#8221; Draper said.
He also hoped to see a day when all the aspects of a business, including accounting, auditing, taxes, bookkeeping and ownership transfer, would be on decentralized blockchain systems.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Project Crypto looks awesome! My hopes to raise a fund all in bitcoin, invest it all in bitcoin, and have startups pay all their employees and suppliers in bitcoin, with all the accounting done on the blockchain with smart contracts is in sight. Imagine, a full ecosystem with all…
&mdash; Tim Draper (@TimDraper) <a href="https://twitter.com/TimDraper/status/1951026677590684063?ref_src=twsrc%5Etfw">July 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/24/12/42511716/bitcoin-as-neutral-reserve-asset-could-overhaul-financial-system-says-analyst" target="_blank" rel="noreferrer noopener">Bitcoin As &#8216;Neutral Reserve Asset&#8217; Could Overhaul Financial System, Says Analyst</a>
Why It Matters: The so-called &#8216;Project Crypto&#8217; initiative aims to overhaul securities regulations <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46770711/sec-launches-project-crypto-heres-what-it-means-for-you">to adapt to blockchain-based financial systems</a>, ensuring that the U.S. stays competitive globally as a hub for innovation and capital formation.
The initiative is a <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46723859/trumps-advisors-just-laid-out-a-crypto-blueprint-heres-whats-in-it">direct follow-up</a> to a report released by President Donald Trump&#8217;s cryptocurrency advisors, which calls for rapid action in areas such as trading, custody and registration to eliminate uncertainty and reduce regulatory friction for digital assets.
Draper has been a vocal advocate for cryptocurrency, and his venture capital firm Draper Associates owns investments in Bitcoin and cryptocurrency exchange Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), according to the company&#8217;s website. 
He predicted earlier in the year that <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44317256/bitcoin-to-hit-250k-by-end-of-2025-tim-draper-predicts-will-be-the-dominant-currency-of-the-world">Bitcoin would hit $250,000</a> by the end of 2025 and become the dominant currency of the world.
Price Action: At the time of writing, BTC was trading at $115,914.48, down 2.06% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/cryptocurrency/25/07/46774943/bitcoin-ethereum-xrp-dogecoin-struggle-as-post-fomc-blues-hits-markets" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Struggle As Post-FOMC Blues Hits Markets</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>
Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

SEC's Project Crypto 'Looks Awesome,' Says Tim Draper As He Pushes For A Bitcoin-Only World With Blockchain Powering Accounting And Payroll

In a strong rebuttal to concerns over pharmaceutical innovation, billionaire Mark Cuban, co-founder of Cost Plus Drugs and Shark Tank fame, argued that slashing pharmacy benefit manager (PBM) fees could paradoxically increase research and development (R&amp;D) funding by allowing manufacturers to earn more.
What Happened: Cuban asserts that brands can earn more by selling directly to his cost-plus model, bypassing the &#8220;insane fees&#8221; and rebates charged by PBMs.
This statement, replying to a query from Parvenu Capital, challenges the long-standing narrative that high U.S. drug prices are essential to sustain R&amp;D.
According to Parvenu Capital, the U.S. shoulders 60-70% of global pharma R&amp;D costs, with only 12% of drugs reaching the market, suggesting current prices amortize failed projects. Thus, the U.S. drugs have higher prices.
Cuban counters that PBMs siphon off profits through rebates and fees, leaving manufacturers with less for R&amp;D. By selling to Cost Plus Drugs at higher net returns, he claims, companies could reinvest more into innovation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Actually the PBMs charge not only rebates , but also insane fees. So the brand manufacturers can sell to us for MORE than they get paid by he PBMs. So they will have MORE money for R&amp;D <a href="https://t.co/xYugLRhChN">https://t.co/xYugLRhChN</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1951124886761644403?ref_src=twsrc%5Etfw">August 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46754175/microsoft-meta-stocks-add-440-billion-in-a-day-nearly-matching-netflixs-entire-503-billion-marke">Microsoft, Meta Stocks Add $440 Billion In A Day—Nearly Matching Netflix&#8217;s Entire $503 Billion Market Cap</a>
Why It Matters: Supporting this, a 2021<a href="https://www.cbo.gov/publication/57126"> Congressional Budget Office</a> report indicates that global sales offset U.S. R&amp;D expenses, hinting that lower domestic prices might shift costs elsewhere without stalling progress. 
Cuban's model, offering <a href="https://www.costplusdrugs.com/medications/sacubitril-valsartan-49-51mg-tablet/">generic Entresto</a>, used to treat heart failure, at just $33.75, exemplifies this shift, contrasting sharply with U.S. prices nearing $600 monthly versus OECD averages of $180. 
As the debate unfolds, Cuban calls for dismantling PBM barriers, promising a future where transparency drives both affordability and innovation.
The Dallas Mavericks owner has been a PBM critic for a long time. He has said "<a href="https://www.benzinga.com/markets/equities/25/06/46021366/mark-cuban-corrects-elizabeth-warren-as-she-slams-jnj-pfe-for-higher-prices-and-zero-taxes-on-big-pharma-pbms-corrupt-healthcare">PBMs corrupt healthcare</a>," explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with three major PBMs negotiating over 90% of rebates for commercial insurance plans. 
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care. He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and "Sh–ing on" independent pharmacies.
Price Acton: Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>40.43%</td>
<td>3.45%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>-2.59%</td>
<td>-19.61%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-50.53%</td>
<td>-56.43%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-3.95%</td>
<td>-12.22%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>0.20%</td>
<td>-4.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-2.74%</td>
<td>-6.70%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-3.40%</td>
<td>-4.43%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>41.31%</td>
<td>46.60%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-3.92%</td>
<td>-10.01%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-22.91%</td>
<td>-31.06%</td>
</tr>
</tbody>
</table>
</figure>
Price Action:&nbsp;The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and&nbsp;Invesco QQQ Trust ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined on Thursday. The SPY was down 0.38% at $632.08, while the QQQ declined 0.53% to $565.01, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
On Friday, the futures of the Dow Jones, S&amp;P 500, and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46687204/warren-buffett-has-56-of-his-258-billion-portfolios-value-exposed-to-ai-here-are-the-5-stocks-that-are-leveraging-ai-within-berkshires-holdings" target="_blank" rel="noreferrer noopener">Warren Buffett Has 56% Of His $258 Billion Portfolio's Value Exposed To AI: Here Are The 5 Stocks That Are Leveraging AI Within Berkshire's Holdings</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Health Care

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'

Press Releases

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Comments

Alterity Therapeutics

Alterity Therapeutics (ATHE) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL